Recent advances in the treatment of functional dyspepsia and irritable bowel syndrome
DOI:
https://doi.org/10.12775/JEHS.2023.43.01.005Keywords
Irritable Bowel Syndrome, Dyspepsia, Pharmacotherapy, Fecal Microbiota Transplantation, PainAbstract
Introduction and purpose:
While irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common problems in everyday clinical practice, their treatment often remains inefficient. The aim of our work is to present the newest discoveries and research conducted in the topic, while putting special accents on methods available in Poland. We decided to refer to British Society of Gastroenterology guidelines of treatment of IBS and FD as commonly accepted treatment standards in Europe.
Description of the state of knowledge:
Number of patients suffering from IBS and FD remains high. According to current research, there are some new therapeutical options in IBS: fecal microbiota transplant, spinal catepsin S, olorinab and tenapanor. Methods already being in use in other applications such as vitamin D supplementation, losartan and fecal microbiota transplant are also being investigated. Fecal microbiota transplant seems the most promising one. There are no new treatment options in FD, however there are new research on already used rifaximin and prokinetics, which show their efficacy. Intensive research is being conducted on the use of herbal medicines in treatment of FD. Even though some papers prove the effectiveness of acupuncture we have decided to omit this topic due to its controversial nature.
Conclusions:
Treatment of IBS and FD remains difficult, there are few advances in that area. Unconventional methods such as herbal medicine and fecal microbiota transplant seem to be gaining in importance.
References
Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697-1723. doi:10.1136/GUTJNL-2022-327737
Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013. doi:10.1038/AJG.2017.154
Medycyna po Dyplomie - Wytyczne w postępowaniu z dyspepsją czynnościową. Accessed June 29, 2023. https://podyplomie.pl/medycyna/31169,wytyczne-w-postepowaniu-z-dyspepsja-czynnosciowa
Rome IV Criteria - Rome Foundation. Accessed July 2, 2023. https://theromefoundation.org/rome-iv/rome-iv-criteria/
[Wyd.13], ed. Interna Szczeklika 2022. Wydawnictwo Medycyna Praktyczna; 2022.
Oka P, Parr H, Barberio B, Black CJ, Savarino E V., Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. lancet Gastroenterol Hepatol. 2020;5(10):908-917. doi:10.1016/S2468-1253(20)30217-X
Jeong H, Lee HR, Yoo BC, Park SM. Manning criteria in irritable bowel syndrome: its diagnostic significance. Korean J Intern Med. 1993;8(1):34-39. doi:10.3904/KJIM.1993.8.1.34
An Evidence-Based Position Statement on the Management of Ir... : Official journal of the American College of Gastroenterology | ACG. Accessed July 2, 2023. https://journals.lww.com/ajg/Fulltext/2009/01001/An_Evidence_Based_Position_Statement_on_the.1.aspx
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. doi:10.1016/J.CGH.2012.02.029
Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology. 1994;107(4):1040-1049. doi:10.1016/0016-5085(94)90228-3
Haque M, Wyeth JW, Stace NH, Talley NJ, Green R. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J. 2000;113(1110):178-181.
Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049-1057. doi:10.1136/GUTJNL-2014-307843
Eusebi LH, Ratnakumaran R, Bazzoli F, Ford AC. Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(1):39-48.e1. doi:10.1016/J.CGH.2017.07.041
Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. doi:10.1136/GUTJNL-2021-324598
Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. doi:10.1053/J.GASTRO.2016.12.039
Downs IA, Aroniadis OC, Kelly L, Brandt LJ. Postinfection Irritable Bowel Syndrome: The Links Between Gastroenteritis, Inflammation, the Microbiome, and Functional Disease. J Clin Gastroenterol. 2017;51(10):869-877. doi:10.1097/MCG.0000000000000924
Lupu VV, Ghiciuc CM, Stefanescu G, et al. Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review. World J Gastroenterol. 2023;29(21):3241. doi:10.3748/WJG.V29.I21.3241
Hong KB, Seo H, Lee JS, Park Y. Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model. BMC Complement Altern Med. 2019;19(1). doi:10.1186/S12906-019-2610-9
Wang YM, Cao YN, Feng LJ, et al. Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. World J Gastroenterol. 2018;24(3):338-350. doi:10.3748/WJG.V24.I3.338
Jin Y, Ren X, Li G, et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33(2):443-452. doi:10.1111/JGH.13841
Tuteja AK, Talley NJ, Stoddard GJ, Verne GN. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome. Dig Dis Sci. 2019;64(3):838-845. doi:10.1007/S10620-018-5344-5
Kohno K, Shirasaka R, Yoshihara K, et al. A spinal microglia population involved in remitting and relapsing neuropathic pain. Science. 2022;376(6588):86-90. doi:10.1126/science.abf6805
Sun P, Lin W, Weng Y, et al. Spinal Cathepsin S promotes visceral hypersensitivity via FKN/CX3CR1/p38 MAPK signaling pathways. Mol Pain. 2023;19:1-12. doi:10.1177/17448069231179118
Payne CD, Deeg MA, Chan M, et al. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Br J Clin Pharmacol. 2014;78(6):1334-1342. doi:10.1111/BCP.12470
Larauche M, Mulak A, Kim YS, Labus J, Million M, Taché Y. Visceral analgesia induced by acute and repeated water avoidance stress in rats: sex difference in opioid involvement. Neurogastroenterol Motil. 2012;24(11):1031. doi:10.1111/J.1365-2982.2012.01980.X
Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(6). doi:10.1111/NMO.13819
Robles-Vera I, Toral M, de la Visitación N, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. Br J Pharmacol. 2020;177(9):2006-2023. doi:10.1111/BPH.14965
Sun Y, Liu X, Wang L, et al. Losartan attenuates acetic acid enema-induced visceral hypersensitivity by inhibiting the ACE1/Ang II/AT1 receptor axis in enteric glial cells. Eur J Pharmacol. 2023;946:175650. doi:10.1016/J.EJPHAR.2023.175650
Yan C, Hu C, Chen X, et al. Vitamin D improves irritable bowel syndrome symptoms: A meta-analysis. Heliyon. 2023;9(6):2405-8440. doi:10.1016/J.HELIYON.2023.E16437
Herekar A, Shimoga D, Jehangir A, et al. Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management. Clin Exp Gastroenterol. 2023;16:79-85. doi:10.2147/CEG.S384251
Tenapanor Reduces IBS Pain Through Inhibition of TRPV1-Depen... : Official journal of the American College of Gastroenterology | ACG. Accessed July 9, 2023. https://journals.lww.com/ajg/Fulltext/2017/10001/Tenapanor_Reduces_IBS_Pain_Through_Inhibition_of.484.aspx
Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360. 2021;2(10):1600-1610. doi:10.34067/KID.0002002021
Dothel G, Chang L, Shih W, et al. µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil. 2019;31(11). doi:10.1111/NMO.13688
Castro J, Garcia-Caraballo S, Maddern J, et al. Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents. Pain. 2022;163(1):E72-E86. doi:10.1097/J.PAIN.0000000000002314
Yacyshyn BR, Hanauer S, Klassen P, et al. Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease. Crohn’s colitis 360. 2020;3(1). doi:10.1093/CROCOL/OTAA089
Chang L, Cash BD, Lembo A, et al. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023;35(5):e14539. doi:10.1111/NMO.14539
Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240-248. doi:10.1111/APT.15330
Wang M, Xie X, Zhao S, Ma X, Wang Z, Zhang Y. Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2023;14. doi:10.3389/FIMMU.2023.1136343
Wu J, Lv L, Wang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol. 2022;12. doi:10.3389/FCIMB.2022.827395
El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation. Gastroenterology. 2022;163(4):982-994.e14. doi:10.1053/J.GASTRO.2022.06.020
Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71-83. doi:10.1111/APT.13236
Halkjær SI, Lo B, Cold F, et al. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World J Gastroenterol. 2023;29(20):3185-3202. doi:10.3748/WJG.V29.I20.3185
Bosman M, Smeets F, Elsenbruch S, et al. Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis. Neurogastroenterol Motil. 2023;35(2). doi:10.1111/NMO.14474
Yang JW, Wang LQ, Zou X, et al. Effect of Acupuncture for Postprandial Distress Syndrome: A Randomized Clinical Trial. Ann Intern Med. 2020;172(12):777-785. doi:10.7326/M19-2880
Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol. 2019;65(3):229-238. doi:10.23736/S1121-421X.19.02567-4
Maev I V., Andreev DN. [Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study]. Ter Arkh. 2021;93(8):897-903. doi:10.26442/00403660.2021.08.200919
Kountouras J, Gavalas E, Papaefthymiou A, et al. Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. Medicina (B Aires). 2020;56(7):1-12. doi:10.3390/MEDICINA56070339
Shrestha DB, Budhathoki P, Subedi P, et al. Acotiamide and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Cureus. 2021;13(12). doi:10.7759/CUREUS.20532
Sinha S, Chary S, Thakur P, et al. Efficacy and Safety of Acotiamide Versus Mosapride in Patients With Functional Dyspepsia Associated With Meal-Induced Postprandial Distress Syndrome: A Phase III Randomized Clinical Trial. Cureus. 2021;13(9). doi:10.7759/CUREUS.18109
Tan VPY, Liu KSH, Lam FYF, Hung IFN, Yuen MF, Leung WK. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2017;45(6):767-776. doi:10.1111/APT.13945
Gurusamy SR, Shah A, Talley NJ, et al. Small Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2021;116(5):935-942. doi:10.14309/AJG.0000000000001197
Shah A, Gurusamy SR, Hansen T, et al. Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia. Dig Dis Sci. 2022;67(6):2299-2309. doi:10.1007/S10620-021-07149-1/METRICS
Tan N, Gwee KA, Tack J, et al. Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta-analysis. J Gastroenterol Hepatol. 2020;35(4):544-556. doi:10.1111/JGH.14905
Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19(3):271-279. doi:10.1111/J.1365-2036.2004.01859.X
Von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102(6):1268-1275. doi:10.1111/J.1572-0241.2006.01183.X
Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol. 2002;40(6):401-408. doi:10.1055/S-2002-32130
Kim K, Ko SJ, Cho SH, Kim J, Park JW. Herbal medicine, Banxia-xiexin tang, for functional dyspepsia: a systematic review and meta-analysis. Front Pharmacol. 2023;14. doi:10.3389/FPHAR.2023.1130257
Ha NY, Ko SJ, Park JW, Kim J. Efficacy and safety of the herbal formula Naesohwajung-tang for functional dyspepsia: a randomized, double-blind, placebo-controlled, multi-center trial. Front Pharmacol. 2023;14. doi:10.3389/FPHAR.2023.1157535/FULL
Inokuchi K, Masaoka T, Kanai T. Rikkunshito as a Therapeautic Agent for Functional Dyspepsia and its Prokinetic and Non-Prokinetic Effects. Front Pharmacol. 2021;12. doi:10.3389/FPHAR.2021.640576
Masuy I, Carbone F, Holvoet L, Vandenberghe A, Vanuytsel T, Tack J. The effect of rikkunshito on gastrointestinal symptoms and gastric motor function: The first study in a Belgian functional dyspepsia population. Neurogastroenterol Motil. 2020;32(2). doi:10.1111/NMO.13739
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jan Bieniasz, Paula Bigos, Konrad Dendys, Wojciech Kuźnicki, Igor Matkowski, Piotr Potyrała
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 526
Number of citations: 0